For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals (MDGL) , Corcept Therapeutics (CORT) , Catalyst Pharmaceuticals (CPRX) , Larimar Therapeutics (LRMR) and Theravance Biopharma (TBPH) .Industry: Small PharmaLink: https://www.zacks.com/commentary/2367138/5-small-drug-stocks-to-buy-as-trump-gets-re-elected?art_rec=quote-stock_overview-zacks_news-ID01-txt-2367138The drug industry witnessed major policy changes during Joe Biden's four-year term as U ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely. However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his pr ...

Corcept Therapeutics Incorporated (CORT) has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024.This company engages in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic and neurologic disorders in the United States. It has spent more than 25 years dedicated to advancing cortisol modulation, resulting in the discovery of more than 1,000 unique selective modulators. Remaining focused on innovation, Corcept i ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 5th:Corcept Therapeutics Incorporated (CORT) : This drugmaker for severe endocrinologic, oncologic, metabolic, and neurologic disorders has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.6% over the last 60 days.Corcept’s shares gained 46.4% over the last three months compared with the S&P 500’s advance of 9.1%. The company possesses a Mome ...

Have you been paying attention to shares of Corcept Therapeutics (CORT) ? Shares have been on the move with the stock up 12.1% over the past month. The stock hit a new 52-week high of $51.32 in the previous session. Corcept Therapeutics has gained 54.1% since the start of the year compared to the 3.1% move for the Zacks Medical sector and the -4.2% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't m ...

Shares of Corcept Therapeutics (CORT) have gained 4.8% over the past four weeks to close the last trading session at $47.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $74.60 indicates a potential upside of 56.7%.The mean estimate comprises five short-term price targets with a standard deviation of $5.18. While the lowest estimate of $67 indicates a 40.7% increase from the ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Investors might want to bet on Corcept Therapeutics (CORT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The upward trend in estimate revisions for this drug developer reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation be ...